Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shenthol Sasankan"'
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1239-1243 (2020)
We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF and P53 mutation, and received dabrafenib a
Externí odkaz:
https://doaj.org/article/64f08a7e689d47d2902d3944f3acc21e
Autor:
Nick Crozier, Shenthol Sasankan, Bernard Tawfik, Janet Abernathy, Neda Hashemi-Sadraei, Richard C. Lauer, Ronald Kittson, Zoneddy Dayao
Publikováno v:
JCO Oncology Practice. 17:e1935-e1942
PURPOSE: Many factors contribute to long wait times for patients on the day of their chemotherapy infusion appointments. Longer wait time leads to nonoptimal care, increased costs, and decreased patient satisfaction. We conducted a quality improvemen
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 3, Pp 1239-1243 (2020)
Case Reports in Oncology, Vol 13, Iss 3, Pp 1239-1243 (2020)
We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF and P53 mutation, and received dabrafenib a
Autor:
Neda Hashemi-Sadraei, Bernard Tawfik, Ronald Kittson, Janet Abernathy, Shenthol Sasankan, Zoneddy Dayao, Nick Crozier, Sandra Peacock, Andrea Cox, Richard C. Lauer
Publikováno v:
Journal of Clinical Oncology. 38:e14042-e14042
e14042 Background: Nationwide, many cancer centers experience challenges with infusion center efficiency while maintaining high safety standards. Many factors contribute to long wait times for patients on the day of their infusion appointments. At Un
Autor:
Tiffany Menhorn, Bernard Tawfik, Neda Hashemi-Sadraei, Amy Zarick-Jones, Richard C. Lauer, Harmony Bowles, Zoneddy Dayao, Nick Crozier, Shenthol Sasankan, Moises Harari Turquie
Publikováno v:
Journal of Clinical Oncology. 38:e19212-e19212
e19212 Background: Oral oncolytics therapy use has been exponentially growing over the last several years necessitating education and monitoring. Pharmacy driven interventions have been shown to increase side effects detection, mitigation and ensure
Publikováno v:
Australasian Medical Journal, Vol 3, Iss 13, Pp 971-971 (2010)